PH12016502221A1 - Aminoester derivatives - Google Patents

Aminoester derivatives

Info

Publication number: PH12016502221A1
Authority: PH; Philippines
Prior art keywords: buffer; edta; hci; tris; resuspended
Prior art date: 2014-06-05

Application number

PH12016502221A

Other languages

English (en)

Inventor

Elisabetta Armani

Gabriele Amari

Carmelida Capaldi

Wesley Blackaby

Ian Linney

De Poel Herve Van

Charles Baker-Glenn

Naimisha Trivedi

Original Assignee

Chiesi Farm Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-06-05

Filing date

2016-11-09

Publication date

2017-02-06

2016-11-09 Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa

2017-02-06 Publication of PH12016502221A1 publication Critical patent/PH12016502221A1/en

Links

239000000872 buffer Substances 0.000 abstract 5
150000001875 compounds Chemical class 0.000 abstract 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 abstract 3
102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 3
108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 3
MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 abstract 2
230000027455 binding Effects 0.000 abstract 2
238000005119 centrifugation Methods 0.000 abstract 2
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 abstract 2
238000002474 experimental method Methods 0.000 abstract 2
239000012528 membrane Substances 0.000 abstract 2
239000008188 pellet Substances 0.000 abstract 2
239000002287 radioligand Substances 0.000 abstract 2
229940122694 Muscarinic M3 receptor antagonist Drugs 0.000 abstract 1
LZCOQTDXKCNBEE-XJMZPCNVSA-N N-methylscopolamine Chemical compound C1([C@@H](CO)C(=O)OC2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)C)=CC=CC=C1 LZCOQTDXKCNBEE-XJMZPCNVSA-N 0.000 abstract 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract 1
229930006000 Sucrose Natural products 0.000 abstract 1
239000007983 Tris buffer Substances 0.000 abstract 1
238000003556 assay Methods 0.000 abstract 1
210000004027 cell Anatomy 0.000 abstract 1
210000001728 clone cell Anatomy 0.000 abstract 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 abstract 1
239000002532 enzyme inhibitor Substances 0.000 abstract 1
238000001914 filtration Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
LZCOQTDXKCNBEE-IKIFYQGPSA-N methscopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)C)=CC=CC=C1 LZCOQTDXKCNBEE-IKIFYQGPSA-N 0.000 abstract 1
229960001383 methylscopolamine Drugs 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
239000003681 muscarinic M3 receptor antagonist Substances 0.000 abstract 1
230000003551 muscarinic effect Effects 0.000 abstract 1
230000009871 nonspecific binding Effects 0.000 abstract 1
239000002953 phosphate buffered saline Substances 0.000 abstract 1
238000000159 protein binding assay Methods 0.000 abstract 1
102000005962 receptors Human genes 0.000 abstract 1
108020003175 receptors Proteins 0.000 abstract 1
239000005720 sucrose Substances 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 abstract 1
238000005406 washing Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Steroid Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Hydrogenated Pyridines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

PH12016502221A 2014-06-05 2016-11-09 Aminoester derivatives PH12016502221A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP14171266		2014-06-05
PCT/EP2015/062417 WO2015185649A1 (en)	2014-06-05	2015-06-03	Aminoester derivatives

Publications (1)

Publication Number	Publication Date
PH12016502221A1 true PH12016502221A1 (en)	2017-02-06

Family

ID=50884281

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PH12016502221A PH12016502221A1 (en)	2014-06-05	2016-11-09	Aminoester derivatives

Country Status (32)

Country	Link
US (2)	US9763924B2 (2)
EP (1)	EP3152201B1 (2)
JP (1)	JP2017516824A (2)
KR (1)	KR102420323B1 (2)
CN (1)	CN106459020B (2)
AR (1)	AR100732A1 (2)
AU (1)	AU2015270539B2 (2)
BR (1)	BR112016026725B1 (2)
CA (1)	CA2953198C (2)
CL (1)	CL2016003117A1 (2)
CY (1)	CY1120698T1 (2)
DK (1)	DK3152201T3 (2)
EA (1)	EA032761B1 (2)
ES (1)	ES2688826T3 (2)
GE (2)	GEAP201814338A (2)
HR (1)	HRP20181967T1 (2)
HU (1)	HUE042119T2 (2)
IL (1)	IL249325B (2)
LT (1)	LT3152201T (2)
MA (1)	MA39947B1 (2)
MX (1)	MX377669B (2)
PE (1)	PE20161557A1 (2)
PH (1)	PH12016502221A1 (2)
PL (1)	PL3152201T3 (2)
PT (1)	PT3152201T (2)
RS (1)	RS57787B1 (2)
SG (1)	SG11201610132RA (2)
SI (1)	SI3152201T1 (2)
TN (1)	TN2016000546A1 (2)
TW (1)	TW201625600A (2)
WO (1)	WO2015185649A1 (2)
ZA (1)	ZA201608331B (2)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2016177849A1 (en)	2015-05-07	2016-11-10	Chiesi Farmaceutici S.P.A.	Aminoester derivatives
AR104822A1 (es) *	2015-06-01	2017-08-16	Chiesi Farm Spa	Derivado de aminoésteres
AR104829A1 (es) *	2015-06-01	2017-08-16	Chiesi Farm Spa	Derivados de aminoésteres
CN106866474B (zh) *	2017-02-16	2018-12-28	陕西师范大学	一种手性α-芳基甘氨酸酯衍生物的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2022783A1 (en) *	2007-08-08	2009-02-11	CHIESI FARMACEUTICI S.p.A.	"Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
UY31637A1 (es)	2008-02-06	2009-08-03		Farmacoforos duales-antagonistas muscarinicos de pde4
EP2216327A1 (en) *	2009-02-06	2010-08-11	CHIESI FARMACEUTICI S.p.A.	Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
CA2893622A1 (en)	2012-12-05	2014-06-12	Chiesi Farmaceutici S.P.A.	Novel compounds
HK1212988A1 (zh) *	2012-12-05	2016-07-22	奇斯药制品公司	作为pde-4抑制剂的苯基乙基吡啶衍生物
CN104837828B (zh)	2012-12-05	2017-07-18	奇斯药制品公司	作为pde4‑抑制剂的苯基乙基吡啶衍生物
ES2655047T3 (es) *	2013-12-05	2018-02-16	Chiesi Farmaceutici S.P.A.	Derivados de heteroarilo para el tratamiento de enfermedades respiratorias
RU2016121852A (ru)	2013-12-05	2017-12-07	КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А.	Производные бензгидрила для лечения респираторных заболеваний

2015
- 2015-05-28 US US14/723,964 patent/US9763924B2/en not_active Expired - Fee Related
- 2015-06-03 HR HRP20181967TT patent/HRP20181967T1/hr unknown
- 2015-06-03 BR BR112016026725-7A patent/BR112016026725B1/pt not_active IP Right Cessation
- 2015-06-03 KR KR1020167032346A patent/KR102420323B1/ko not_active Expired - Fee Related
- 2015-06-03 CA CA2953198A patent/CA2953198C/en active Active
- 2015-06-03 DK DK15731261.2T patent/DK3152201T3/en active
- 2015-06-03 RS RS20181192A patent/RS57787B1/sr unknown
- 2015-06-03 PL PL15731261T patent/PL3152201T3/pl unknown
- 2015-06-03 EA EA201692227A patent/EA032761B1/ru not_active IP Right Cessation
- 2015-06-03 SI SI201530392T patent/SI3152201T1/sl unknown
- 2015-06-03 PE PE2016002520A patent/PE20161557A1/es unknown
- 2015-06-03 GE GEAP201814338A patent/GEAP201814338A/en unknown
- 2015-06-03 HU HUE15731261A patent/HUE042119T2/hu unknown
- 2015-06-03 MX MX2016015958A patent/MX377669B/es active IP Right Grant
- 2015-06-03 TN TN2016000546A patent/TN2016000546A1/en unknown
- 2015-06-03 LT LTEP15731261.2T patent/LT3152201T/lt unknown
- 2015-06-03 AU AU2015270539A patent/AU2015270539B2/en not_active Expired - Fee Related
- 2015-06-03 CN CN201580029748.7A patent/CN106459020B/zh not_active Expired - Fee Related
- 2015-06-03 WO PCT/EP2015/062417 patent/WO2015185649A1/en not_active Ceased
- 2015-06-03 GE GEAP201514338A patent/GEP20186922B/en unknown
- 2015-06-03 JP JP2016571037A patent/JP2017516824A/ja not_active Withdrawn
- 2015-06-03 ES ES15731261.2T patent/ES2688826T3/es active Active
- 2015-06-03 MA MA39947A patent/MA39947B1/fr unknown
- 2015-06-03 PT PT15731261T patent/PT3152201T/pt unknown
- 2015-06-03 EP EP15731261.2A patent/EP3152201B1/en active Active
- 2015-06-03 SG SG11201610132RA patent/SG11201610132RA/en unknown
- 2015-06-04 AR ARP150101772A patent/AR100732A1/es unknown
- 2015-06-04 TW TW104118107A patent/TW201625600A/zh unknown
2016
- 2016-11-09 PH PH12016502221A patent/PH12016502221A1/en unknown
- 2016-12-01 IL IL249325A patent/IL249325B/en not_active IP Right Cessation
- 2016-12-02 ZA ZA2016/08331A patent/ZA201608331B/en unknown
- 2016-12-02 CL CL2016003117A patent/CL2016003117A1/es unknown
2017
- 2017-08-10 US US15/673,710 patent/US10117860B2/en active Active
2018
- 2018-09-24 CY CY181100984T patent/CY1120698T1/el unknown

Also Published As

Publication number	Publication date
US10117860B2 (en)	2018-11-06
BR112016026725A8 (pt)	2021-06-29
IL249325B (en)	2018-12-31
US9763924B2 (en)	2017-09-19
CA2953198A1 (en)	2015-12-10
AR100732A1 (es)	2016-10-26
CN106459020B (zh)	2019-06-18
AU2015270539A1 (en)	2016-12-22
MX377669B (es)	2025-03-11
MX2016015958A (es)	2017-04-10
SI3152201T1 (sl)	2018-10-30
CL2016003117A1 (es)	2017-06-23
TN2016000546A1 (en)	2018-04-04
MA39947B1 (fr)	2018-10-31
EA032761B1 (ru)	2019-07-31
EP3152201B1 (en)	2018-08-29
RS57787B1 (sr)	2018-12-31
SG11201610132RA (en)	2017-01-27
US20150352091A1 (en)	2015-12-10
LT3152201T (lt)	2018-10-10
KR20170015294A (ko)	2017-02-08
EA201692227A1 (ru)	2017-05-31
DK3152201T3 (en)	2018-11-19
HRP20181967T1 (hr)	2019-02-08
AU2015270539B2 (en)	2018-11-08
WO2015185649A1 (en)	2015-12-10
EP3152201A1 (en)	2017-04-12
TW201625600A (zh)	2016-07-16
GEAP201814338A (en)	2018-07-25
KR102420323B1 (ko)	2022-07-13
PT3152201T (pt)	2018-10-26
HUE042119T2 (hu)	2019-06-28
ZA201608331B (en)	2018-05-30
PL3152201T3 (pl)	2019-02-28
CN106459020A (zh)	2017-02-22
CA2953198C (en)	2023-06-13
JP2017516824A (ja)	2017-06-22
GEP20186922B (en)	2018-11-12
ES2688826T3 (es)	2018-11-07
PE20161557A1 (es)	2017-02-07
IL249325A0 (en)	2017-02-28
US20170340616A1 (en)	2017-11-30
WO2015185649A9 (en)	2017-01-05
MA39947A (fr)	2017-04-12
BR112016026725A2 (pt)	2017-08-15
BR112016026725B1 (pt)	2024-02-27
CY1120698T1 (el)	2019-12-11

Publication	Publication Date	Title
PH12016502221A1 (en)	2017-02-06	Aminoester derivatives
CA2868907C (en)	2022-01-04	Anti-hla-b*27 antibodies and uses thereof
WO2009003493A3 (en)	2009-02-26	Mhc multimers, methods for their generation, labeling and use
PH12015501420A1 (en)	2015-09-21	Human anti-tau antibodies
HK1223629A1 (zh)	2017-08-04	Bcma及cd3结合分子
WO2013011011A3 (en)	2013-05-02	Method of reversibly staining a target cell
Thorsheim et al.	2015	Chemistry of xylopyranosides
WO2009123762A3 (en)	2009-12-30	Method of screening single cells for the production of biologically active agents
EP3623385A8 (en)	2020-05-06	Binding molecules for bcma and cd3
WO2013177118A3 (en)	2014-03-06	Novel purification of non-human antibodies using protein a affinity chromatography
MY182355A (en)	2021-01-20	Hmo synthesis
MY181284A (en)	2020-12-21	Methods for cementing in a subterranean formation using a cement composition containing calcium silicate hydrate seeds
WO2010039802A3 (en)	2010-07-15	Methods and compositions for isolating nucleic acid
Sołtysik et al.	2015	ERα36–another piece of the estrogen puzzle
WO2009033163A3 (en)	2009-05-22	Borrelia diagnostics and screening methods
WO2010114239A3 (ko)	2010-11-25	도로의 면형 데이터를 이용한 맵 매칭장치 및 그 방법
WO2011018586A3 (fr)	2011-04-07	Methode de determination de la liaison d'un compose donne a un recepteur membranaire.
Jean-Charles et al.	2016	Chapter nine-cellular roles of beta-arrestins as substrates and adaptors of ubiquitination and deubiquitination
WO2011143575A3 (en)	2012-03-08	smFRET WITH MEMBRANE PROTEINS
WO2011055897A3 (en)	2011-10-27	Fusion protein binding specifically to constant region of antibody, preparation thereof and method for isolating antibody using the same
WO2012096552A3 (ko)	2012-10-04	Ｒｅｘ１을 포함하는 세포 리프로그래밍 조성물 및 이를 이용한 유도 만능줄기세포 제조방법
WO2012168344A8 (en)	2013-03-14	BINDING COMPOUNDS TO HUMAN β1-ADRENORECEPTOR (β1-AR) AND THEIR USE IN THE MEASUREMENT OF AUTO-ANTI-βA1-AR ANTIBODIES
WO2010141604A3 (en)	2011-03-03	Combinatorial discovery of enzymes with utility in biomass transformation
WO2010129728A3 (en)	2011-04-28	Articles with shell structures including a cell extractant and biodetection methods thereof
WO2013085540A3 (en)	2014-04-10	Cry crystals for the production of antimicrobial proteins